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b2-Adrenoceptor Activation Modulates Skin Wound
Healing Processes to Reduce Scarring
Gabrielle S. Le Provost1 and Christine E. Pullar1
During wound healing, excessive inflammation, angiogenesis, and differentiated human dermal fibroblast (HDF )
function contribute to scarring, whereas hyperpigmentation negatively affects scar quality. Over 100 million
patients heal with a scar every year. To investigate the role of the beta 2 adrenergic receptor (b2AR) in wound
scarring, the ability of beta 2 adrenergic receptor agonist (b2ARag) to alter HDF differentiation and function,
wound inflammation, angiogenesis, and wound scarring was explored in HDFs, zebrafish, chick chorioallantoic
membrane assay (CAM), and a porcine skin wound model, respectively. Here we identify a b2AR-mediated
mechanism for scar reduction. b2ARag significantly reduced HDF differentiation, via multiple cAMP and/or
fibroblast growth factor 2 or basic FGF (FGF2)-dependent mechanisms, in the presence of transforming growth
factor betab1, reduced contractile function, and inhibited mRNA expression of a number of profibrotic markers.
b2ARag also reduced inflammation and angiogenesis in zebrafish and CAMs in vivo, respectively. In Red Duroc
pig full-thickness wounds, b2ARag reduced both scar area and hyperpigmentation by almost 50% and
significantly improved scar quality. Indeed, mechanisms delineated in vitro and in other in vivo models were
evident in the b2ARag-treated porcine scars in vivo. Both macrophage infiltration and angiogenesis were initially
decreased, whereas DF function was impaired in the b2ARag-treated porcine wound bed. These data collectively
reveal the potential of b2ARag to improve skin scarring.
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INTRODUCTION
Wound repair is complex, requiring the coordinated action of
numerous cell types and physiological processes to facilitate
healing. In contrast to the perfect regeneration in embryonic
wounds (Redd et al., 2004), adult wounds heal with fibrotic
scars (Shaw and Martin, 2009). Evolution has primed repair
processes to heal quickly, but imperfectly (Stramer et al.,
2007). Excessive inflammation (Stramer et al., 2007),
angiogenesis (DiPietro, 2013), and DF function (Hinz, 2007)
all contribute to scarring. Annually, 100 million patients, in
the developed world, heal with scars after elective procedures,
trauma, and burn injuries, causing serious cosmetic/functional
problems, which are emotionally and physically debilitating,
placing hefty financial burdens on Healthcare Systems (Bayat
et al., 2003).
Beta-adrenergic receptor familys (bARs: b1AR; b2AR; b3AR
(Wallukat, 2002)) are G protein–coupled receptors for cate-
cholamines released from the adrenal medulla and sympa-
thetic nervous system (Nagatsu and Stjarne, 1998), but they
are also synthesized and secreted by keratinocytes (Pullar
et al., 2006b). As bARs are highly expressed on most skin
cells, an autocrine (epidermis) and paracrine (dermis) bAR
skin network exists (Pullar et al., 2008). Moreover, beta 2
adrenergic receptor agonist (b2ARag) may protect patients
from developing venous leg ulcers (Margolis et al., 2007).
bARs can influence wound healing processes. bARag
reduced re-epithelialization of clipped mouse tails, where
healing lacks a dermal component (Pullar et al., 2006a). In
contrast, bAR antagonism promoted skin re-epithelialization
(Pullar et al., 2006b) in ex vivo models of chronic wound
re-epithelialization (Kratz, 1998) and murine skin burn models
in vivo (Sivamani et al., 2009) and accelerated skin barrier
recovery (Denda et al., 2003). Indeed, bAR antagonism and
beta 2 adrenergic receptor (b2AR) gene deletion both
promoted very early stages of murine wound healing in vivo
(Pullar et al., 2012), and bAR antagonism has successfully
healed chronic wounds (Tang et al., 2012; Braun et al., 2013;
Lev-Tov et al., 2013; Manahan et al., 2014).
No previous study has addressed the role of b2AR in wound
scarring. The b2ARag Salbutamol is a safe and widely used
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asthma medication (Boskabady and Saadatinejad, 2003).
Here, the effect of b2ARag on DF differentiation and function,
inflammation (zebrafish wounds) (Renshaw et al., 2006), and
angiogenesis (chick chorioallantoic membrane assay (CAM))
(Ausprunk et al., 1974) was investigated. Furthermore, as
porcine skin is anatomically similar to human skin
(Montagna and Yun, 1964), the effect of Salbutamol on
wound scarring was explored in the Red Duroc pig, a
widely used model for evaluating human scar reduction
interventions (Gallant-Behm et al., 2008).
RESULTS
b2ARag reduces human dermal fibroblast (HDF) differentiation
and contractile function in vitro via cAMP and fibroblast growth
factor 2 or basic FGF (FGF2)-dependent mechanisms
HDF smooth muscle a-actin (SMA) expression, a differentiated
fibroblast–myofibroblast marker (Hinz et al., 2001), was
analyzed by immunocytochemistry. After 48 hours in basal
medium, 1.5% of cells were positive for SMA, whereas partial
(Salbutamol, 57%) and full (Formoterol, 39%) b2ARags
(Baker, 2010) decreased the ratio of SMA-positive HDFs
(Supplementary Figure S1a online). Previously, a nonselective
bARag reduced HDF contractile function in floating collagen
gels (Pullar and Isseroff, 2005). Here, using restrained-collagen
gels, where gel tension promotes differentiation (Tomasek
et al., 2002), b2ARag significantly reduced gel contraction
(Supplementary Figure S1b online).
Transforming growth factor beta (TGFb)1, a fibroblast
differentiation promoter strongly upregulated in wounds
(Hinz, 2007), increased the ratio of SMA-positive HDFs by
14.5-fold (Figure 1a). Regardless of whether the b2ARag was
added 6 hours prior or subsequent to TGFb1 for a further
42 hours, similar, marked inhibition was observed, decreasing
the ratio of SMA-positive HDFs by up to 95% (Figure 1a).
A b2ARag-mediated decrease in TGFb1 secretion could
underpin its reduction in HDF SMA expression. TGFb1 was
detected in the HDF supernatant, but there was no b2ARag-
mediated effect (Supplementary Figure S2a online). FGF2 can
reduce myofibroblast function (Ishiguro et al., 2009; Tiede
et al., 2009). b2ARag increased FGF2 secretion by 4.3- and
0.59-fold after 6 and 24 hours, respectively (Figure 1b).
Indeed, exogenous FGF2 alone decreased the ratio of SMA-
positive HDFs by 79% (Figure 1c). HDFs express the FGF2
receptor fibroblast growth factor receptor1 (Takenaka et al.,
2002). Treatment with the fibroblast growth factor receptor1
inhibitor PD173074 (PD) (Miyake et al., 2010) increased the
ratio of SMA-expressing HDFs by 2-fold (Figure 1c). Mean-
while, in the presence of PD, b2ARag no longer reduced SMA-
positive HDF numbers, both in the presence and absence of
TGFb1 (Figure 1c, Supplementary Figure S2b online).
b2ARs can couple to Gas, increasing intracellular cAMP
(Scott et al., 1999). A cAMP analog (sp-cAMP) alone
decreased SMA-positive HDFs by 40% (Figure 1d,
Supplementary Figure S2c online), whereas a cAMP analog
that inhibits protein kinase A (rp-cAMP) (Dostmann et al.,
1990) had no significant effect alone, but completely
prevented the b2ARag-mediated reduction in SMA-
expressing HDFs (Figure 1d, Supplementary Figure S2c
online), suggesting that the mechanism was cAMP and protein
kinase A dependent.
To investigate downstream signaling through mitogen-acti-
vated protein kinases (MAPK), experiments were performed in
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Figure 1. b2AR agonist (b2ARag) reduces human dermal fibroblast (HDF) differentiation and contractile function in vitro via cAMP- and fibroblast growth factor
2 or basic FGF (FGF2)-dependent mechanisms. HDFs were treated with serum-free medium (SFM) alone or SFM containing Salbutamol/Formoterol (10mM), TGFb1
(1 ng ml1), FGF2 (10 ng ml1), PD173074 FGFR inhibitor (PD173074,50nM), sp-cAMP/rp-cAMP (50mM), alone or pretreated, as indicated. (a) HDFs were treated
for 48 hours with TGFb1 alone or 6 hours pretreatment with TGFb1 or b2ARag before b2ARag or TGFb1 addition, respectively, for 42 hours. Ratios of smooth
muscle a actin (SMA)-positive cells to total cells were normalized to control. Scale bar¼100mm. (b) HDF FGF2 secretion was ELISA analyzed 6/24 hours post
treatment in the presence or absence of b2ARag. (c) HDFs were treated for 48 hours with FGF2, PD, or b2ARag, with/without 6 hours of PD pretreatment. (d) HDFs
were treated for 2 hours with sp-cAMP, rp-cAMP, or b2ARag, with/without rp-cAMP pretreatment, 30 minutes before b2ARag for 2 hours. Data presented are
means±SEM; 4 independent experiments. NS, not significant.
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the presence of selective inhibitors of MEK1/2 (U0126), p38
MAP kinase (SB202190), or JNK (JNK inhibitor VIII, which
inhibits JNK1/2/3). Inhibiting the MAP kinases individually had
no effect and did not prevent the b2ARag-mediated reduction
in the number of SMA-expressing HDFs (Supplementary
Figure S2d online).
b2ARag reduces the number of mature focal adhesions on the
HDF periphery and profibrotic gene expression
Tension is a major driver of fibroblast differentiation (Hinz,
2007). Mature focal adhesions (MFAs) facilitate tension-
sensing in the immediate fibroblast environment. Within
high-tension, healing wounds, differentiating fibroblasts
develop larger SMFAs (8–30mm), with superior contractile
ability compared with MFAs (4–8mm) (Dugina et al., 2001).
To determine whether b2ARag altered the number of M/
supermature focal adhesion (SMFAs), the length of FAs at the
HDF periphery was analyzed. b2ARag reduced both periph-
eral HDF MFA and SMFA numbers by 23 and 58%, respec-
tively (Figure 2a). PD was used to probe FGF2 involvement,
and it had no effect alone and it did not prevent the b2ARag-
mediated reduction in M/SMFA numbers (Figure 2a). How-
ever, exogenous FGF2 also reduced HDF peripheral MFA and
SMFA numbers by 29 and 63%, respectively, whereas PD
completely prevented any decrease (Figure 2b).
Similar to the SMA studies above, the use of rp-cAMP
prevented the b2ARag-mediated reduction in M/SMFA num-
bers, demonstrating that the underpinning mechanism was
cAMP dependent (Figure 2c) but independent of MAP kinases
(Supplementary Figure S2e online). Overall, b2ARag reduced
M/SMFA numbers directly via cAMP-mediated and indirectly
via FGF2-mediated (Figure 1b) pathways. Additional
experiments demonstrated that the b2ARag-mediated reduc-
tion in gel contraction was also partly FGF2 dependent
(Supplementary Figure S2f online).
To determine whether b2ARag altered HDF profibrotic
capability, RT-PCR was performed for profibrotic genes
(Hinz, 2007). Salbutamol and Formoterol decreased SMA,
fibronectin (FN) EDA, type I collagenA1, TGFb1, and
connective tissue growth factor (CCN2) gene expression by
24 to 49% and increased FGF2 gene expression by 1.2- and
2.1-fold, respectively, after 6 hours (Figure 2d). No effects on
TGFb2, TGFb3, COL1A2, PDGF-A, MMP2, or decorin gene
expression were observed (results not shown). In addition,
whereas TGFb1 decreased HDF b2AR gene expression by
73%, FGF2 increased b2AR expression by 1.5-fold
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Figure 2. b2AR agonist (b2ARag) reduces the number of mature FAs on the human dermal fibroblast (HDF) periphery and profibrotic gene expression. HDFs
were treated with serum-free medium (SFM) alone or containing b2ARag (Salbutamol, 10mM), fibroblast growth factor 2 or basic FGF (FGF2) (10ngml 1),
PD173074 FGFR inhibitor (PD) (50nM), sp-cAMP, rp-cAMP (50mM), alone for 15 minutes or with pretreatment, as indicated. HDFs were pretreated with PD (a, b)
or rp-cAMP (c) for 30 minutes, and then with b2ARag (a, c) or FGF2 (b) for a further 15 minutes. Mature (top) and supermature (bottom) FAs were measured and
counted. Representative pictures are shown. Scale bar¼ 10mm. Data are presented as mean±SEM from at least 4 independent experiments (*Po0.05, **Po0.01).
HDF gene expression was analyzed by RT-PCR, 6 hours post treatment with b2ARag (Salbutamol, Formoterol, 10mM), in SFM. Mean mRNA levels were
normalized to control values. Data are presented as mean±SEM from at least four independent experiments (*Po0.05, **Po0.01). CCN2, connective tissue
growth factor; COL1A1, type 1 collagen, alpha 1; FGF2, fibroblast growth factor 2; FN EDA, fibronectin (FN) EDA; NS, not significant; SMA, smooth muscle
a actin; TGFb1, transforming growth factor beta 1.
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(Supplementary Figure S2g online). Apart from the b2ARag-
mediated increase in FGF2 gene expression, all changes were
independent of FGF2 (Supplementary Figure S2h online).
b2ARag reduces zebrafish inflammation and embryonic chick
angiogenesis
Excessive wound inflammation contributes to scarring (Stramer
et al., 2007). A zebrafish tail wound model was used to
visualize neutrophil guidance to wounds in real time (Renshaw
et al., 2006). b2ARag reduced neutrophil recruitment by 60%
after 6 hours (Supplementary Figure S3a online).
Although angiogenesis is essential for wound repair,
reduced angiogenesis is linked with improved healing
(DiPietro, 2013) and less angiogenesis occurs in nonscarring
oral wounds (Szpaderska et al., 2005) and scarless fetal
wounds (Wilgus et al., 2008). b2ARag significantly reduced
angiogenesis in the chick chorioallantoic membrane assay
(CAM) by 29% (Supplementary Figure S3b online).
b2ARag altered the open wound area within the first 14 days of
wound healing but did not affect the re-epithelialization of full-
thickness Red Duroc pig wounds
The effect of b2ARag on wound scarring was tested in a
porcine skin wound model. Similar to humans, Red Durocs
heal wounds with excessive collagen fiber formation (Gallant-
Behm and Hart, 2006), generating raised hyperpigmented
scars (Gallant et al., 2004). Twenty full-thickness wounds
were created along each back (Figure 4a); pigs were rando-
mized and treated daily with vehicle alone or containing 5 mM
Salbutamol sulfate. Two wounds/animal were biopsied weekly
initially (7/14/21/28/42 days post wounding), and all wounds
were digitally photographed. Remaining scars were photo-
graphed and collected 56 days post wounding.
Calibrated digital wound pictures were used to determine
the open wound area. b2ARag-treated open wound area was
11% smaller and appeared less red and swollen than controls,
at 7 days post wounding (Figure 3a). After 14 days, b2ARag-
treated open wound area was 23% larger, but there was no
significant difference in the open wound area after 28 days,
when wounds were almost completely healed (Figure 3a).
Re-epithelialization rates could not be assessed 7 days post
wounding, but they were similar in both groups after 14 or 28
days and almost all wounds were completely re-epithelialized
by 28 days post wounding (Figure 3b).
b2ARag reduces scar area and improves the appearance of Red
Duroc scars
Scars were visible from day 28 onward, and scar area was
measured from calibrated digital pictures in a double-blind
manner. One scar (1–10, control/b2ARag, Figure 4a), closest
to the average scar area at that position, is presented alongside
a mask delineating scar area (Figure 4b). b2ARag reduced scar
area by 34, 38, and 47%, 28, 42, and 56 days post wounding,
respectively (Figure 4c). Tension worsens scarring (Ogawa
et al., 2011) and varies along the porcine back, with the
highest tension most caudally (positions 9/10). Indeed,
wounds in positions 9/10 had scars almost twice the size of
wounds in the most cranial positions, 1/2 (Figure 4b and d).
Moreover, b2ARag reduced scar area by 50% in the highest
tension positions (9/10) (Figure 4d).
Scar appearance, evaluated by hyperpigmentation, color
match, sheen, height, texture, and pliability, was scored in a
double-blind manner (Supplementary Table S1 online). The
three less pigmented wounds at position 10 in both groups are
presented (Figure 4e). b2ARag improved pigmentation (48%),
color match (44%), sheen (53%), height (34%), texture (22%),
and pliability (22%) (Figure 4f). Furthermore, hyperpigmenta-
tion was maximal in wounds at positions of highest tension (9/
10) and significantly improved at all scar positions in the
b2ARag-treated pigs (Figure 4g).
Immunohistochemistry reveals a reduction in profibrotic
mechanisms underpinning the b2ARag-mediated scar reduction
Wound inflammation was investigated using both the
macrophage a-naphtyl acetate esterase (a-NAE) stain and an
anti-macrophage antibody, CD163, specific for the M2 alter-
natively activated/healer macrophages (Weisser et al., 2013).
a-NAE staining revealed an 18% decrease in biopsy
macrophage-infiltrated area, after 7 days, in b2ARag-treated
wounds (Figure 5a). In contrast, after 14 days, b2ARag
treatment increased the macrophage-infiltrated area by 28%
(Figure 5a). From 21 to 56 days post wounding, there was no
difference in macrophage-infiltrated area between groups
(Figure 5a). At 14 days post wounding, CD163-specific
staining appeared similar to the a-NAE staining (Figure 5b).
Discrete blood vessels were detected by anti-von
Willebrand factor (vWF) immunohistochemistry and counted
within defined areas of biopsies/excised scars. After 7 days,
the number of discrete vWF-stained structures decreased by
22% in b2ARag-treated biopsies (Figure 5c). Similar to the
pattern observed with macrophage infiltration, b2ARag
increased discrete vWF-stained structure density by 2-fold,
after 14 days (Figure 5c). In contrast, after 21/28/42 days,
discrete vWF-stained structure densities were lower in
b2ARag-treated biopsies (Figure 5c). By 56 days post wound-
ing, angiogenesis was markedly reduced in all wounds, and
there was no difference in vWF-stained structure density
between groups at the end of study (Figure 5d). Biopsies were
stained with the proliferation marker Ki67, but no differences
were observed between groups (results not shown).
Collagen deposition and fiber formation were analyzed by
histology on cranial–caudal cross-sections of whole excised
scars to observe the entire wound bed, 56 days post wound-
ing. Masson’s trichrome stain was used to detect the presence
(green) and absence (red) of collagen fibrillar structures within
the wound bed. In b2ARag-treated wounds, the area without
collagen fibers was 1.5-fold larger than in control-treated
wounds (Figure 5e), but there was no difference in COL1
staining between groups (Supplementary Figure S4a online).
Biopsies, from day 14 onward, were positively stained for
SMA and FN EDA, markers of DF profibrotic phenotype (Hinz,
2007). The wound bed area positively stained for SMA and FN
EDA was almost halved in b2ARag-treated scars (Figure 5f
and g). However, there was no difference in COL3 (not
shown) or CCN2 (downstream of TGFb1) staining between
groups (Supplementary Figure S4b online). To investigate
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underpinning mechanisms for reducing fibroblast differentia-
tion, FGF2 staining was performed on excised scars. FGF2
staining intensity was 2-fold higher in the b2ARag-treated
wound bed (Figure 5h).
DISCUSSION
b2ARag restrained mechanisms that contribute to scarring,
including HDF differentiation and function in vitro, and
inflammation (zebrafish) and angiogenesis (chick chorioallan-
toic membrane assay (CAM)) in vivo. Moreover, in Red Duroc
pigs, Salbutamol significantly reduced wound scarring by 47%,
56 days post wounding. Histology confirmed that b2ARag
initially reduced inflammation and angiogenesis, whereas DF
function was restrained in the wound dermis. Indeed, at the
end of study, scar area and hyperpigmentation were reduced
by almost half, and scar appearance was significantly
improved in b2ARag-treated wounds compared with controls.
In vitro, b2ARag reduced HDF profibrotic nature by
impairing their ability to sense tension within the wound
(reduced peripheral MFA and SMFA numbers) and reduced
profibrotic gene expression (SMA, FN EDA, TGFb1, CCN2,
type I collagenA1), leading to a reduction in differentiation via
cAMP and/or FGF2 dependent and MAPK-independent
mechanisms, resulting in reduced contractile function
(Figures 1 and 2, Supplementary Figures S1 and S2 online).
Indeed, b2ARag increased HDF FGF2 mRNA expression and
secretion in vitro (Figures 1b and 2d) and increased FGF2
staining intensity in excised scars (Figure 5h).
Recently, cAMP was highlighted as a regulator in tissue
fibrosis (Insel et al., 2012) and FGF2, highly expressed in
scarless fetal skin (Chen et al., 2006), reduced scarring in
human acute incisional wounds (Ono et al., 2007). The b2AR-
mediated increases in cAMP and FGF2 were likely highly
beneficial in steering wound healing toward regeneration and
away from scarring in the porcine full-thickness wounds.
Here, b2ARag reduced inflammatory cell guidance to
zebrafish wounds in vivo within hours post wounding
(Supplementary Figure S3a online) and reduced the macro-
phage-infiltrated area in 7-day porcine wound biopsies, the
earliest time point that biopsies could be taken from the
porcine wound edge (Figure 5a). However, the macrophage-
infiltrated area was actually 28% larger in b2ARag-treated
wounds, 14 days post wounding, compared with controls,
whereas there was no difference from day 21 onward
(Figure 5a). The main macrophage phenotypes, characterized
in murine models, are classically activated killer macrophages
(M1), or alternatively activated healer macrophages (M2)
(Weisser et al., 2013), although subsets of these phenotypes
exist in wounds (Sindrilaru and Scharffetter-Kochanek, 2013).
Murine M2 can be identified by CD163 expression, also
identified on pig macrophage populations (Fairbairn et al.,
2013). In the present study, the pattern of macrophage staining
with a-NAE and CD163 was identical 14 days post wounding,
suggesting that all biopsy macrophages expressed CD163
(Figure 5b). Therefore, either M2 alone is recruited to porcine
wounds, perhaps contributing to the b2ARag-mediated scar
reduction, or CD163 is not a phenotype-specific pig M2
marker. The effect of b2ARag on angiogenesis and macro-
phage infiltration appeared highly correlated (Figure 5a and b).
M2 macrophages promote wound angiogenesis (Lucas et al.,
2010), and macrophages are necessary to stimulate and fuse
tip cells at the leading edge of angiogenic sprouts (Fantin
et al., 2010). It is possible that the b2ARag-mediated increase
in CD163-expressing macrophages, 14 days post wounding,
facilitated the large increase in angiogenesis observed in the
b2ARag-treated wounds at this time point.
b2ARag-treated and control wounds re-epithelialized at the
same rate from day 14 onward (Figure 4b). Previously, an
early bARag-mediated delay in murine skin wound re-epithe-
lialization was observed (Pullar et al., 2006a; Sivamani et al.,
2009). Perhaps we missed an early delay in this study. Rodent
skin is untethered, however, and wounds heal primarily by
wound contraction (Hayward and Robson, 1991); therefore, a
bAR-mediated reduction in wound contraction (Pullar and
Isseroff, 2005) (Figure 3a) could have underpinned this delay
in murine models. In contrast, porcine and human skin
wounds close primarily by wound re-epithelialization
(Sullivan et al., 2001).
Histology confirmed that b2ARag had restrained DF differ-
entiation in excised scars; the area of the dermis stained for
SMA/FN EDA was significantly reduced, whereas FGF2 stain-
ing intensity was increased 2-fold (Figure 5f–h). In addition,
after 14 days, b2ARag-treated wounds were larger, suggesting
a reduction in wound contraction. Mechanisms delineated
in vitro, underpinning the b2ARag-mediated reduction in
DF differentiation/function, appeared operational in vivo
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(Figure 5f–h). Moreover, Masson’s trichrome staining revealed
a 1.5-fold increase in wound bed area without collagen fibers,
but no significant difference in the collagen I staining,
suggesting that b2ARag had not altered collagen I deposition
in the neodermis but had delayed the incorporation of collagen
I into fibers (Figure 5e, Supplementary Figure S4a online).
Keloids and hypertrophic scars contain a large increase
in collagen fibers and bundles (Tuan and Nichter, 1998);
therefore, the b2ARag-mediated reduction in collagen fiber
formation perhaps contributed to the reduced scar area and
improved scar appearance.
b2ARag also reduced scar hyperpigmentation and improved
sheen, height, texture, and pliability (Figure 4). Indeed, knock-
down of Adrb2a, a b2AR ortholog expressed in zebrafish brain
and epidermis, induced significant hypopigmentation, reveal-
ing a functional b2AR role in pigmentation (Wang et al.,
2009). Inflammation is essential for zebrafish wound
hyperpigmentation (Levesque et al., 2013). Here, b2ARag
reduced inflammation (Supplementary Figures S3a, Figure 5a
and b online), which could have contributed to the reduced
hyperpigmentation; future work will address this.
In conclusion, our work highlights the b2AR as a regulator
of wound healing/scarring. There are currently no clinically
tested or licensed interventions/pharmaceuticals available to
reduce wound scarring/fibrosis or to improve scar hyperpig-
mentation. Topical Salbutamol significantly improved acute
skin scarring in vivo and could have significant potential as a
treatment. Future work will address the potential to improve
hypertrophic scarring, keloid formation, and organ fibrosis.
MATERIALS AND METHODS
Ethics statement
Scar study was performed under UK Home Office License (40/3535).
Local ethics approval was obtained from The University of Notting-
ham ACUC.
Animals
Adult zebrafish were maintained in compliance with the Animals
(Scientific Procedures) Act, 1986. Embryos were collected and raised
in 28.5 1C egg water until the required developmental stage
(Westerfield, 1994; Kimmel et al., 1995).
Ten female, 3-month-old Red Duroc pigs (30–35 kg) were pur-
chased from a certified breeder. Animals were acclimatized the week
before study commencement and were maintained on a standard diet.
Cell culture
Three HDF strains (Invitrogen, Paisley, UK), passages 3–15, were used
throughout. HDFs were maintained at 37 1C in a humidified atmo-
sphere of 5% CO2, as subconfluent monolayers in fibroblast complete
Figure 5. Immunohistochemistry (IHC) reveals a reduction in profibrotic
mechanisms underpinning the b2AR agonist (b2ARag)-mediated scar
reduction. a-Naphtyl acetate esterase (a-NAE) staining (all biopsies) (a) and
CD163 IHC (day 14 biopsies) (b) determined the percentage of wound bed
macrophage-infiltrated area. Angiogenesis was assessed by von Willebrand
factor (vWF) IHC (all biopsies) (c) and day 56 excised scars (d). vWF-positive
discrete blood vessel density was determined within defined wound bed areas.
Masson’s trichrome staining, smooth muscle a actin (SMA), fibronectin (FN)
EDA, and fibroblast growth factor 2 or basic FGF (FGF2) IHC were performed
on day 56 excised scars. Wound bed area (defined from H&E staining (not
shown)) without collagen fibers (red) was measured. (e) SMA and FN EDA
positive-stained wound bed area was measured (f, g). FGF2 expression was
evaluated using an intensity score (0–2) (h). Representative figures and
graphical quantification are shown (2 biopsies/N¼ 5 (biopsies); 10 scars/N¼ 5
(excised scars)). Lines demarcate the wound bed. Scale bar¼1 mm. Data are
presented as mean±SEM (*Po0.05, **Po0.01, ***Po0.001). NS, not
significant.
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medium: Dulbecco’s modified Eagle’s medium, 0.5% antibiotic
solution, and 10% fetal bovine serum (Invitrogen). Sometimes
serum-free medium (SFM) was used. All drugs were purchased from
Tocris (Bristol, UK), except FGF2 and TGFb1 (Promocell, Heidelberg,
Germany).
Quantitative RT-PCR
11,500 HDFcm 2 were plated into dishes, reaching 80% confluency
within 48 hours, and then serum-starved overnight, before
treatment in SFM alone or supplemented with Salbutamol or
Formoterol (10mM). At 6 hours post treatment, total RNA was isolated
(Nucleospin RNA II kit, Macherey Nagel, Duren, Germany) with
DNase treatment. A measure of 1mg of total RNA was reverse-
transcribed using oligo-dT (NanoScript RT kit, Primer Design, South-
ampton, UK). Duplicate PCR reactions were performed with 10 ng of
cDNA, 300 nM primers, and SYBR green Precision MasterMix
(Primer Design) on a LightCycler 480 (Roche, Welwyn, UK), followed
by a melting curve. Type I collagenA1, CCN2, FGF2, SMA, and
TGF-b1 primers were purchased from Primer Design, whereas
primers for b2AR and FN EDA were custom-designed using
NCBI Primer Blast and synthesized by Sigma-Aldrich (Gillingham,
UK). Reference genes CYC1 and UBE2D2 were selected using a
geNorm kit (Primer Design) and qBaseþ software (Biogazelle;
Zwijnaarde, Belgium). Using the average Cq of CYC1 and UBE2D2
for normalization, mRNA relative expression level was calculated by
the 2DDCq method.
ELISA
HDFs were plated on collagen I–coated (30mgml 1, Invitrogen) 6-
well plates and incubated for 24 hours in fibroblast complete medium
to 80% confluency, and then washed and serum-starved for 24 hours
before incubation with SFM alone or SFM containing 10mM Salbuta-
mol for 6 or 24 hours. Supernatant growth factor levels were
determined using human Duoset ELISA kits (R&D Systems).
Immunocytochemistry
SMA Immunocytochemistry: 8,500 HDFcm 2 were plated on sterile
coverslips for 24 hours in fibroblast complete medium, then serum-
starved, overnight. Pretreatment was applied for 6 hours with either
SFM alone or SFM containing Formoterol/Salbutamol (10mM), TGFb1
(1 ng/ml), FGF2 (10 ng/ml), or PD173074 (50 nM), before adding
TGFb1 (1 ng/ml) or Salbutamol (10mM) for a further 42 hours, as per
combinations stated in the figures. sp-cAMP or rp-cAMP (50mM) were
applied for 30 minutes before treatment with SFM alone or SFM
containing 10mM Salbutamol for 2 hours. Cells were fixed in ice-cold
methanol for 10 minutes and blocked for 1 hour with 2% donkey
serum/5% BSA.
Vinculin Immunocytochemistry (FAs): 2,150 HDF/cm2 were plated
and serum-starved as above. Pretreatment was applied for 30 minutes
in SFM alone or SFM containing PD173074 (50 nM), sp-cAMP (50mM),
or rp-cAMP, before treatment with Salbutamol (10mM) or FGF2
(10 ng/ml) for 15 minutes. Cells were fixed in 4% paraformaldehyde
(10 minutes), permeabilized in 0.1% Triton X-100 (5 minutes), and
blocked (1 hour) with 5% donkey serum.
Mouse anti-SMA (1:500, A2547, Sigma) or anti-vinculin antibody
(1:100, V9131, Sigma) were incubated for 2 hours at room tempera-
ture, followed by incubation with Alexa Fluor 488 donkey anti-mouse
IgG secondary antibody (1:500, A-21202, Invitrogen) for 1 hour.
Coverslips were mounted using ProLong Gold containing DAPI
(Invitrogen). Image acquisition was performed on a Nikon Eclipse
TE2000-E microscope using the Volocity software (Improvision,
Perkin Elmer).
Analyses were performed on 20 separate random fields from
duplicate samples, per condition. The mean ratio of SMA-positive
HDFs/total HDFs was determined using Volocity, counting total
DAPI-stained nuclei and SMA-positive HDF numbers, within defined
fluorescence thresholds in blue and green channels, respectively. On
20 HDF per experiment (n¼ 4), FAs were counted and measured
manually on calibrated pictures using Volocity, then classified
according to their length: immature (o4mm), mature (4–8mm) and
supermature FAs (48mm) (Dugina et al., 2001). Only peripheral FAs
were measured.
Scar protocol
Ten Red Durocs were fasted for 12 hours before surgery and provided
premedication/anesthesia and analgesia as advised by the vet.
Premedication comprised detomidine (0.1 mgkg 1; Orion Pharma,
Newbury, UK), ketamine (5 mgkg 1; Vetoquinol, Buckingham, UK),
and buprenorphine (0.05 mgkg 1; Animalcare Ltd, York, UK);
anesthesia included alfaxan (0.7–2.4 mgkg 1; Jurox, Malvern, UK)
and inhaled isoflourane (Abbot Laboratories, Maidenhead, UK).
Lidocaine hydrocholride (1% w/v; Hameln Pharmaceuticals, Glou-
cester, UK) was administered directly into wounds after surgery.
Buprenorphine (0.05 mgkg 1) was provided intramuscularly every
8 hours, and meloxicam (0.4 mgkg 1; Boehringer Ingelheim, Brack-
nell, UK) was provided intramuscularly, daily, for the first 48 hours
post surgery and then was administered orally, daily (0.4 mgkg 1).
Animals were placed in ventral recumbency, and their backs were
shaved and washed with skin prep. Twenty 2 2 cm2 full-thickness
wounds were created in 5 rows and 4 columns down the back, with a
minimum of 2.5 cm between each wound (Figure 4a) (Gallant-Behm
et al., 2008). Using a scalpel and metal guide, the skin, including
subcutaneous fat, was removed exposing the underlying fascia.
Wound corners and the edge centers were marked with ink tattoos
and animals were randomized into two groups. A volume of 500ml of
Granugel (Convatec, Uxbridge, UK) diluted 2:1 in sterile water, alone
(controls) or containing 5 mM Salbutamol sulfate (1.2 mgml 1
Salbutamol), was freshly prepared and added to each wound after
surgery and daily thereafter.
Wounds were covered with a new dressing daily (Steroplast,
Manchester, UK) and custom jackets (Agenda Group, Hull, UK) for
study duration.
On days 7,14,21,28,42 post wounding, animals were provided
with analgesia/anesthesia, skin was shaved, each wound was digitally
photographed, and four 6-mm punch biopsies (Miltex, Weymouth,
UK) were taken from 2 wounds/animal, as shown in (Figure 4a). On
day 56 post wounding, animals were provided with analgesia/
anesthesia, skin was shaved, and each wound was digitally photo-
graphed and assessed for scar appearance. Animals were then
euthanized using a schedule 1 method, and the remaining ten
scars/animal were harvested for histology.
Wound healing and scar formation assessment
Wound healing and scar area were analyzed from calibrated wound
photographs in a double-blind manner, using Adobe Photoshop.
Wound area was measured from day 7 to day 28, using the wound
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edges marked by tattoos. Re-epithelialized area was calculated at
days 14/28 by measuring the non-re-epithelialized area of the wound,
dividing it by the wound area at day 0, and multiplying it by 100, to
obtain the percentage non-re-epithelialized area, which was then
subtracted from 100 to give % re-epithelialization.
Visible scar area was measured from day 28 to day 56. Hyperpig-
mented, red, raised, or damaged skin at the wound site was included
in the scar area. Scar assessment was performed at day 56 before
animal euthanasia using a composite of the Manchester (Beausang
et al., 1998) and Vancouver (Sullivan et al., 1990) scar scales with
modifications for porcine wounds (Supplementary Table S1 online).
The results are presented as mean values/scoresþ / SEM (n¼ 10 for
biopsies; n¼ 50 for excised scars).
Immunohistochemistry
Excised biopsies were snap-frozen in liquid nitrogen, whereas excised
scars were halved along the cranial–caudal axis and embedded in
Tissue Tek OCT compound (Sakura Finetek, Thatcham, UK) before
freezing in isopentane. 10-mm-thick frozen sections were air-dried for
30 minutes and fixed in acetone, before staining with H&E or
Masson’s trichrome. Macrophage infiltration was detected by a-
NAE staining (kit 91-A, Sigma-Aldrich). Immunohistochemistry was
performed on acetone-fixed sections using the Histostain-Plus IHC
Detection Kit (Invitrogen) with anti-vWF ab6994 (Abcam, Cambridge,
UK), anti-SMA (A2547, Sigma), anti-FN EDA ab6328, anti-COL1
ab90395, anti-FGF2 ab181, anti-collagen III ab23445, anti-CCN2
ab6992, and anti-CD163 MCA2311GA (Serotec, Hemel Hempstead,
UK), and incubated overnight at 4 1C. Sections were counterstained
with Mayer’s haematoxylin before dehydration and mounting.
Brightfield pictures of scar sections were acquired on a Zeiss
Axiovert 200 microscope with the Axiovision 4.8 software using
multiacquisition stitching. Calibrated images were analyzed with
Adobe Photoshop (Maidenhead, UK). Neo-collagen fiber deposition
was determined by measuring collagen fiber negative areas (red),
within the dermis (defined from H&E sections), in the Masson’s
trichrome staining. Neo-angiogenesis was determined by the number
of discrete vWF-stained structures counted within a 0.25 mm2
(biopsies) or 1 mm2 (excised scars) area within the most densely
stained area (biopsies) or wound bed directly below the epidermis
(excised scars). Inflammation was assessed by the % macrophage-
infiltrated area of the biopsy (NAE/anti-CD163 staining) or wound bed
(excised scars). The wound bed on excised scar sections was defined
from H&E-stained sections and demarcated on Figure 5d–h and
Supplementary Figure S4a and b online with a black line.
Statistical analysis
Statistical significance was analyzed using the GraphPad
Prism6 software (La Jolla, CA). Data distribution was first assessed
using the D’Agostino & Pearson normality test. Continuous variables
were analyzed with the two-tailed unpaired Student’s t-test (Gaussian
distributions), with a Welch’s correction for unequal variances
when necessary, or with the nonparametric Mann–Whitney test
(non-Gaussian distributions). One or two categorical variables were
analyzed by one-way or two-way ANOVA (Gaussian distributions),
with the Bonferroni’s post-test, or by the Kruskal–Wallis test (non-
Gaussian distributions) with a Dunn’s post-test. Values are presented
as meanþ / SEM, with statistical significance ascribed as *Po0.05/
**Po0.01/***Po0.001.
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